Maria E. Reig

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 184 publications

Corrigendum to "Direct-acting antivirals lower mortality and recurrence in HCV-related hepatocellular carcinoma post liver resection: A multicenter international study" [Surgery 183 (2025) 109396].

Corrigendum to "Direct-acting antivirals lower mortality and recurrence in HCV-related hepatocellular carcinoma post liver resection: A multicenter international study" [Surgery 183 (2025) 109396].

Journal: Surgery

Published: May 29, 2026

Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcomes From a Multinational Cohort.

Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcomes From a Multinational Cohort.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 15, 2026

Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer).

Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer).

Journal: Future oncology (London, England)

Published: May 11, 2026

Corrigendum to "Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes" [Eur J Cancer (May) (2025) 15:221:115404].

Corrigendum to "Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes" [Eur J Cancer (May) (2025) 15:221:115404].

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 03, 2026

Erratum to 'BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update' [J Hepatol (2026) 631-654].

Erratum to 'BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update' [J Hepatol (2026) 631-654].

Journal: Journal of hepatology

Published: April 05, 2026

Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.

Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.

Journal: Journal of hematology & oncology

Published: March 25, 2026

Immunogenicity of neoantigens from hepatocellular carcinoma patients treated with a combined radioimmunotherapy.

Immunogenicity of neoantigens from hepatocellular carcinoma patients treated with a combined radioimmunotherapy.

Journal: Oncoimmunology

Published: March 19, 2026

Optimizing Liver Cancer Care Through BCLC Principles.

Optimizing Liver Cancer Care Through BCLC Principles.

Journal: Seminars in liver disease

Published: February 27, 2026

Correction: Lymphocyte exhaustion in hepatocellular carcinoma: a dynamic evolution across disease stages.

Correction: Lymphocyte exhaustion in hepatocellular carcinoma: a dynamic evolution across disease stages.

Journal: Frontiers in immunology

Published: January 29, 2026

A phase Ib/2a study of fostrox in combination with lenvatinib as second line therapy in patients with advanced hepatocellular carcinoma.

A phase Ib/2a study of fostrox in combination with lenvatinib as second line therapy in patients with advanced hepatocellular carcinoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 23, 2026

A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma.

A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 23, 2026

Beyond second-line therapy: Strategic sequencing of systemic treatments in advanced hepatocellular carcinoma.

Beyond second-line therapy: Strategic sequencing of systemic treatments in advanced hepatocellular carcinoma.

Journal: Hepatology (Baltimore, Md.)

Published: December 12, 2025

Showing 1-12 of 184

Last Updated: 09/26/2026